Allient (ALNT) Competitors

Allient (NASDAQ:ALNT) and 10x Genomics (NASDAQ:TXG) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Do insiders & institutionals believe in ALNT or TXG?

61.6% of Allient shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 15.6% of Allient shares are owned by company insiders. Comparatively, 9.4% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is ALNT or TXG more profitable?

Allient has a net margin of 2.64% compared to 10x Genomics' net margin of -29.90%. Allient's return on equity of 10.80% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	2.64%	10.80%	4.75%
10x Genomics	-29.90%	-25.40%	-19.69%

Do analysts recommend ALNT or TXG?

Allient presently has a consensus price target of $31.00, suggesting a potential downside of 10.79%. 10x Genomics has a consensus price target of $15.81, suggesting a potential upside of 46.64%. Given 10x Genomics' higher possible upside, analysts plainly believe 10x Genomics is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
10x Genomics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

Which has better earnings & valuation, ALNT or TXG?

Allient has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$516.06M	1.14	$24.10M	$0.59	58.90
10x Genomics	$624.66M	2.12	-$182.63M	-$1.30	-8.29

Does the media favor ALNT or TXG?

In the previous week, 10x Genomics had 1 more articles in the media than Allient. MarketBeat recorded 6 mentions for 10x Genomics and 5 mentions for Allient. Allient's average media sentiment score of 1.35 beat 10x Genomics' score of 0.31 indicating that Allient is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer ALNT or TXG?

10x Genomics received 60 more outperform votes than Allient when rated by MarketBeat users. However, 54.55% of users gave Allient an outperform vote while only 50.00% of users gave 10x Genomics an outperform vote.

Company	Underperform	Outperform
Allient	Outperform Votes 6 54.55%	Underperform Votes 5 45.45%
10x Genomics	Outperform Votes 66 50.00%	Underperform Votes 66 50.00%

Which has more volatility and risk, ALNT or TXG?

Allient has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.

Summary

Allient beats 10x Genomics on 10 of the 18 factors compared between the two stocks.